Categories: HealthcareNews

PBC Biomed Appoints Mark McMahan as Chief Commercial Officer

SHANNON, Ireland, Oct. 06, 2025 (GLOBE NEWSWIRE) — Irish medical device company PBC Biomed today announced the appointment of Mark McMahan as Chief Commercial Officer, effective October 2025. McMahan, formerly Vice President of Global & US Trauma & Extremities Marketing at Smith & Nephew, brings extensive international expertise in medical device commercialization and strategy.

In his new role, McMahan will oversee global commercialization strategies for PBC Biomed’s proprietary technologies, including OsStic® bioadhesive, ARC, and VAPS. He will also lead commercial planning for client products, such as the ReFeel™ nerve repair solution, supporting the company’s expanding portfolio of innovative medical technologies.

Paul Burke, Managing Partner at PBC Biomed, commented:

“This announcement reflects PBC Biomed’s commitment to advancing our global presence and building strong commercial pathways for our technologies and client products. Mark’s experience and leadership will be invaluable as we continue to scale and deliver transformative solutions in the medical device space.”

Mark McMahan added:

“This announcement marks a major milestone in my career, and I am thrilled to join PBC Biomed at such an exciting stage of growth. The company’s technologies have the potential to redefine standards in surgical repair and patient recovery, and I look forward to driving their commercial success worldwide.”

Learn more about the PBC Biomed leadership team here: https://pbcbiomed.com/company/

About PBC Biomed:

PBC Biomed is a leading biomedical company dedicated to advancing healthcare through innovation. With a diverse portfolio of products and solutions spanning multiple medical disciplines, we are committed to improving patient outcomes and enhancing quality of life. For more information, visit www.pbcbiomed.com.

Contact Details
Bronagh O’Doherty
Global Product Manager, PBC Biomed
Bronagh@pbcbiomed.com

Staff

Recent Posts

Is SynergyRx GLP-1 Legitimate? Platform Lists Compounded Semaglutide at $200 With Oral Tablet Options

Telehealth Provider Offers FDA-Approved and Compounded Weight Loss Medications in All 50 States, Subject to…

10 hours ago

Direct Meds GLP-1 Medications Platform Maintains LegitScript Certification as New Year Weight Loss Interest Peaks Amid Compounding Regulatory Shifts

Telehealth Platform Facilitates Compounded Semaglutide and Tirzepatide Access Through Licensed Provider Evaluation as FDA Shortage…

10 hours ago

Best Peptides for Boosting Growth Hormone: ReadyRx Lists Prescription Sermorelin in Injectable and Needle-Free Formats for 2026

Analysis examines best peptides for boosting growth hormone as ReadyRx lists prescription sermorelin in injectable…

10 hours ago

Best Fat Burner For Men 2026: Effective Fat Burning Supplements For Men’s Belly Fat Launched By Wolfson Brands Ltd

Discover the best fat burner for men in 2025. Explore Wolfson Brand’s effective fat-burning supplements…

10 hours ago

MEDIROM Partners with World

Deploying “Proof of Human” Infrastructure throughout Japan, a Technology Envisioned by Sam Altman and Alex…

10 hours ago